What Does Catalyst Do?
Catalyst Pharmaceuticals is a Coral Gables, Florida-based commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases. Founded in 2002, it markets three drugs: FIRDAPSE® (amifampridine) — the only FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare muscle weakness disease; FYCOMPA® (perampanel) — an epilepsy drug acquired from Eisai; and AGAMREE® (vamorolone) — a newer treatment for Duchenne Muscular Dystrophy. Its model is built around licensing, developing, and commercialising rare disease drugs in the US, Canada, and Japan.
BQ Score — Business Quality
Financial Performance
Revenue has grown consistently, driven mainly by FIRDAPSE and the newer AGAMREE launch. Operating margins have stabilised around 44–45% in recent quarters — a healthy level for a commercial-stage pharma company of this size.
| Period | Rev Growth | Op Margin | Net Margin | FCF Yield |
|---|
| FY 2024 | +40% | 40% | 33% | Strong |
| Q1 2025 | +44% | 45% | 40% | Strong |
| Q2 2025 | +19% | 45% | 36% | Strong |
| Q3 2025 | +15% | 44% | 36% | Strong |
Strong Valuation vs Peers
Trading at a P/E of 13.65× against an industry average of 23.29× — and at just 12.25× free cash flow. The stock screens as genuinely cheap on a pure earnings and cash flow basis. 6 analysts all rate it a Buy, with a consensus target of $34.86 vs current $23.34 — implying ~49% upside.
Revenue Breakdown
Three products drive nearly all revenue. FIRDAPSE remains the core contributor (~58–63% of product revenue), FYCOMPA adds ~16–25%, and AGAMREE is growing fast from a small base — up 113–1194% year-on-year depending on the quarter (off a very low starting point).
AGAMREE Growth Watch
AGAMREE was newly launched and is growing triple digits. If it scales successfully in DMD (Duchenne Muscular Dystrophy), it could materially reduce FIRDAPSE dependency over 3–5 years. This is the upside scenario to watch.
Key Risks
Risk 1 — Patent Cliff (Binary Risk)
FIRDAPSE exclusivity was extended to 2035 through settlements with Teva and Lupin — but the Hetero trial (March 2026) could invalidate key patents and enable much earlier generic entry. This is a binary legal event that could materially impair Catalyst's primary revenue stream.
Risk 2 — Revenue Concentration
72% of net revenue comes from a single distributor. Additionally, FIRDAPSE alone accounts for roughly 60% of product revenue. This double concentration — one drug, one distributor — creates meaningful fragility in the business model.
Risk 3 — FYCOMPA Patent Expiry
FYCOMPA was generating ~$137M annually but nears patent expiration in May 2025, which has already begun reducing its contribution. This headwind is visible in the Q3 2025 data where FYCOMPA revenue fell 28% year-on-year.
What's Working
Strong returns: ROA 23.86%, ROE 27.52%, ROIC 23.58%. Zero long-term debt. $200M share repurchase authorised through Dec 2026. Full-year 2025 guidance raised to $565–585M after Q3 strength. AGAMREE growing rapidly from base.
Analyst View
All 6 covering analysts rate CPRX a Buy with targets ranging from $32 to $40, averaging $34.86. Projected revenue growth of 17.52% in 2025 and 7.21% in 2026. Four consecutive positive earnings surprises. The market is pricing in significant patent risk discount — which is why the valuation looks anomalously cheap.
Easy Equity Verdict
Fundamentally strong, but the risk profile is too high to ignore right now.
Catalyst's financials are genuinely healthy — strong margins, excellent capital efficiency, and cheap valuation. But the combination of FIRDAPSE patent risk (Hetero trial, March 2026), FYCOMPA decline, and 72% single-distributor concentration creates a high-risk setup. The upside is real if patent clarity resolves in Catalyst's favour. Until then, we prefer to wait for the Hetero trial outcome and evidence of AGAMREE reaching meaningful scale before considering entry.